vTv Therapeutics Announces Licensing Agreement for Novel Nrf2 Activator to Anteris Bio
HIGH POINT, N.C., Dec. 15, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC (“vTv”) has entered into a licensing agreement with Anteris Bio for worldwide rights to vTv’s novel clinical-stage Nrf2 activator compound, HPP971. Anteris Bio, a newly-formed portfolio company of Aditum Bio, the biotech investment firm co-founded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research (NIBR) Dr. Mark Fishman, will focus on developing HPP971 as a new therapy for the treatment of renal disease.
HPP971 is vTv’s most advanced oral, small molecule activator of the Nrf2 pathway (nuclear factor erythroid 2-related factor 2) within its portfolio of promising Nrf2 compounds. HPP971 has completed two phase 1 studies to date. Under the terms of the agreement, Anteris will pay vTv an upfront payment of $2 million and vTv may be eligible for up to $151 million of future development, regulatory and commercial sales milestones, as well as royalties on annual net sales at a low double-digit rate in exchange for worldwide development and commercialization rights to the compound. In addition, vTv will receive a minority equity interest in Anteris Bio.
“The Nrf2 pathway is a promising, novel target for combating many diseases related to oxidative stress, including renal disease,” said Steve Holcombe, president and chief executive officer of vTv Therapeutics. “We’re thrilled to partner with Anteris to further the development of HPP971. With a focus in renal disease and a strategic partnership with TrialSpark, they will have the ability to efficiently develop HPP971 to ultimately bring a potential new treatment option to patients suffering from kidney disease.”
Chronic kidney disease (CKD) is one of the most significant global health challenges and a leading cause of mortality, both directly and as a key risk factor for cardiovascular disease. Globally, it is estimated that nearly 700 million individuals suffer from CKD, and CKD is directly responsible for over 1 million deaths annually. Clear unmet medical need exists in renal disease as therapies have traditionally revolved around treatment of symptoms (e.g. hypertension, renal failure). HPP971, to be renamed ANT-401, is a small molecule activator of Nrf2, a mechanism which has disease modifying potential across multiple etiologies of renal disease. Nrf2 is a transcription factor required for the expression of many antioxidant genes regulated by the ARE promoter sequence. ANT-401 activates Nrf2 through the inhibition of Bach1, a transcription repressor that prevents Nrf2 activity in the nucleus.
vTv will continue to explore further internal development and partnership opportunities for the remaining molecules in its portfolio of Nrf2 activators.
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment of type 1 diabetes, Alzheimer’s disease, and inflammatory disorders. vTv’s development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary disease (COPD), and genetic mitochondrial diseases. For more information, please visit www.vtvtherapeutics.com or follow us on Twitter: @vTvTherapeutics.
About Aditum Bio
Aditum Bio is committed to improving public health by accelerating R&D in disease areas with both large and more targeted patient populations, where medical innovation can have a huge impact. Aditum Bio focuses on basic mechanisms of disease, in-licenses promising drug candidates directed at such pathophysiologies, and spins-out individual companies dedicated to bringing each candidate through Phase II clinical trials. In partnership with TrialSpark, a technology driven research company that can complete clinical trials faster and at a lower cost than traditional trials, Aditum Bio uses data, software and technology to help bring innovative medicines through the clinical trial phase more quickly and with lower costs than traditional pharmaceutical companies.
For more information, please visit www.aditumbio.com.
This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures or investments we may undertake. We qualify all of our forward-looking statements by these cautionary statements.